Cindy Eide

Researcher 6
Senior Scientist, Department of Pediatrics

Cindy Eide

Contact Info

Researcher 6
Senior Scientist
, Department of Pediatrics


Summary

Research Interests: stem cells, cell therapy, transplantation, GVHD, cancer, genetic disorders, epidermolysis bullosa, Fanconi anemia, induced pluripotent stem cells, directed differentiation, disease modeling and therapy, genetic correction

Research

Research Summary/Interests

Stem cells, cell therapy, transplantation, GVHD, cancer, genetic disorders, epidermolysis bullosa, Fanconi anemia, induced pluripotent stem cells, directed differentiation, disease modeling and therapy, genetic correction

Publications

  • 1.Webber BR, O’Connor KT, McElmurry RT, Durgin EN, Eide C, Lees CJ, Riddle MJ, Mathews W, Frank N, Kluth MA, Ganss C, Moriarity BS, Frank M, Osborn MJ, Tolar J.“Immune modulation alleviates symptoms of dystrophic epidermolysis bullosa.”(2016) Submitted to JEM
  • 2.Tolar J, Webber B, Osborn M, McElroy A, Lonetree C, DeFeo A, Patel D, Xia L, Eide C, Lees C, McElmurry R, Riddle M, Blazar B, Twaroski K, Kim CJ“CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.” npg Regenerative Medicine (2016) accepted
  • 3.Lindborg BA, Brekke JH, Vegoe AL, Ulrich CB, Haider KT, Subramaniam S, Venhuizen SL, Eide CR, Orchard PJ, Chen W, Wang Q, Pelaez F, Scott CM, Kokkoli E, Keirstead SA, Dutton JR, Tolar J, O'Brien TD.Rapid Induction of Cerebral Organoids From Human Induced Pluripotent Stem Cells Using a Chemically Defined Hydrogel and Defined Cell Culture Medium.Stem Cells Transl Med. 2016 Jul;5(7):970-9. doi: 10.5966/sctm.2015-0305. PMID: 2717757
  • 4.Ramirez P, Wagner JE, DeFor TE, Eide CR, Miller JS, Weisdorf DJ, Brunstein CG.“CXCR4 expression in CD34+ cells and unit predominance after double umbilical cord blood transplantation. “ Leukemia (2012), 1-3 doi: 1038/leu.2012.261

  • 5.Tolar J, Park IH, Xia L, Lees CJ, Peacock B, Webber B, McElmurry RT, Eide CR, Orchard PJ, Kyba M, Osborn MJ, Lund TC, Wagner JE, Daley GQ, Blazar BR. “Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome).” Blood. 2010 Oct 29
  • 6.Tolar J, Xia L, Riddle MJ, Lees CJ, Eide CR, McElmurry RT, Titeux M, Osborn MJ, Lund TC, Hovnanian A, Wagner JE, Blazar BR. “Induced Pluripotent Stem Cells from Individuals with Recessive Dystrophic Epidermolysis Bullosa. “ J. Invest. Dermatol. 2010 DEC 2.
  • 7.Wagner JE, Barker JN, DeFor T, Baker KS, Blazar BR, Eide C, Goldman A, Kersey J, Krivit W, MacMillan M, Orchard P, Peters C, Weisdorf DJ, Ramsay NKC, Davies SM. “Transplantation of Unrelated Donor Umbilical Cord Blood in 102 Patients with Malignant and Non-Malignant Diseases: Influence of CD34 Cell Dose and HLA Disparity on Treatment-Related Mortality and Survival. “ Blood advanced on line publication. Blood. 100:1611-8 (2002).
  • 8.Gregory JJ, Wagner JE, Verlander PC, Levran O, Batish SD, Eide CR, Steffenhagen A, Hirsch B, Auerbach AD. “Somatic Mosaicism in Fanconi Anemia: Evidence of Genotypic Reversion in Lymphohematopoietic Stem Cells.”Proc Nat Acad Sci. 98:2532-2537 (2001).
  • 9.Chan CH, Blazar BR, Eide CR, Greenfield L, Krietman RJ, Vallera DA. “Reactivity of murine cytokine fusion toxin, DT 390 -mIL-3, with bone marrow progenitor cells. “ Blood 88:1445, 1996
  • 10.Vallera DA, Panoskaltsis-Mortari A, Yost C, Ramakrishnan S, Eide CR, Kreitman R, Nicholls PJ, Pennell C, Blazar BR: “Anti-graft-versus-host disease effect of DT 390 -anti-CD3sFv, a single chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T cell receptor.” Blood 88:2342, 1996
  • 11.Chan C-H, Blazar BR, Eide CR, Kreitman RJ, Vallera DA: “A murine cytokine fusion toxin specifically targeting the murine GM-CSF receptor on normal committed bone marrow progenitor cells and GM-CSF dependent tumor cells.”Blood 86:2732, 1995
  • 12.Serie J.R., Hegre O.D., Eide C.R., Weinhaus A.J., Marshall S. “The successful allotransplantation of neonatal rat islets across multiple combined major and minor histocompatibility barriers.” Transplantation 44: p.739-741. 1987.